Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Probiotics for Enhanced Tissue Carotenoid Status in Premenopausal Women (ProCar)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04511052
Recruitment Status : Recruiting
First Posted : August 12, 2020
Last Update Posted : September 5, 2021
Sponsor:
Collaborator:
Lallemand Health Solutions
Information provided by (Responsible Party):
McGill University

Brief Summary:

Carotenoids are yellow-orange fat soluble plant pigments primarily obtained from the diet that serve as an accurate biomarker for fruit and vegetable intake. Carotenoids have demonstrated antioxidant, anti-inflammatory, and anti-obesogenic properties among others. Excess carotenoids are deposited in the skin for storage where they protect against UV skin damage and contribute to improvements in skin health (i.e., decrease the appearance of wrinkles). However, carotenoid status is linked to bioavailability and absorption, which has a high inter-individual variability. It has been hypothesized that inter-individual variations are related to the diversity of gut microbiota.

The aim of the present study is to determine whether probiotic supplementation can enhance carotenoid status and responsiveness to carotenoid-mediated changes in blood and skin from intake of a supplement containing mixed forms of carotenoids in pre-menopausal women.


Condition or disease Intervention/treatment Phase
Carotenoid Status Gut Microbiome Skin Health Dietary Supplement: Probiotic Other: Placebo Dietary Supplement: Carotenoid supplement Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Screening
Official Title: Probiotics for Enhanced Tissue Carotenoid Status: a Double-blind, Randomized, Controlled Trial
Estimated Study Start Date : September 2021
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : June 2022

Arm Intervention/treatment
Experimental: Carotenoid + Probiotic

Carotenoid: 1 capsule daily of a mixed carotenoid (~ 20 mg total carotenoids) supplement

Probiotic: 1 capsule daily containing 10 x 10^9 CFU of a proprietary strain

Total duration: 10 weeks

Dietary Supplement: Probiotic
Daily intake of 10 x 10^9 CFU of a proprietary strain for a total duration of 10 weeks

Dietary Supplement: Carotenoid supplement
1 capsule daily containing ~20 mg of total carotenoids for a total duration of 10 weeks

Placebo Comparator: Carotenoid + Placebo

Carotenoid: 1 capsule daily of a mixed carotenoid (~ 20 mg total carotenoids) supplement

Placebo: 1 capsule daily containing the same carrier material of the probiotic, that is also similar in size, shape, and taste.

Total duration: 10 weeks

Other: Placebo
1 capsule daily containing the same carrier material that is similar in size, shape and taste to the probiotic, for a duration of 10 weeks

Dietary Supplement: Carotenoid supplement
1 capsule daily containing ~20 mg of total carotenoids for a total duration of 10 weeks




Primary Outcome Measures :
  1. Changes in skin yellow color saturation measured by a spectrophotometer [ Time Frame: Week 0, 5, and 10 ]
    Average b* value (yellow coloration designated by the CIELab color space) measured from the palm and forehead by spectrophotometry


Secondary Outcome Measures :
  1. Changes in blood plasma carotenoid status [ Time Frame: Week 0, 5, and 10 ]
    Blood plasma HPLC or LC-MS analysis

  2. Changes in yellow skin color saturation measured by image analysis [ Time Frame: Week 0, 5, and 10 ]
    Average b* value (yellow coloration designated by the CIELab color space) measured by image analysis of the palm and forehead

  3. Changes in fecal microbial composition [ Time Frame: Week -2, 0, 5, and 10 ]
    16s rRNA sequencing

  4. Changes in recovery of probiotic strain [ Time Frame: Week -2, 0, 5, and 10 ]
    16s rRNA qPCR

  5. Changes in skin hydration [ Time Frame: Week 0, 5, and 10 ]
    Measured using a Courage + Khazaka probe system

  6. Changes in skin elasticity [ Time Frame: Week 0, 5, and 10 ]
    Measured using the Tewameter probe from Courage + Khazaka probe system

  7. Changes in skin trans-epidermal water loss [ Time Frame: Week 0, 5, and 10 ]
    Measured using a Courage + Khazaka probe system

  8. Changes in facial skin wrinkling [ Time Frame: Week 0, 5, and 10 ]
    Images of participants will be individually rated by two trained specialists based on the skin aging atlas 1 - Caucasian type book at four different regions: forehead, crow's feet, nasolabial fold, and upper lip

  9. Changes in plasma interleukin 1β (IL-1β) levels [ Time Frame: Week 0, 5, and 10 ]
    Assessed with MILLIPLEX MAP Human High Sensitivity T Cell Panel - Immunology Multiplex Assay.

  10. Changes in plasma interleukin-6 (IL-6) levels [ Time Frame: Week 0, 5, and 10 ]
    Assessed with MILLIPLEX MAP Human High Sensitivity T Cell Panel - Immunology Multiplex Assay.

  11. Changes in plasma interleukin-8 (IL-8) levels [ Time Frame: Week 0, 5, and 10 ]
    Assessed with MILLIPLEX MAP Human High Sensitivity T Cell Panel - Immunology Multiplex Assay

  12. Changes in plasma tumor necrosis factor- α (TNF-α) levels [ Time Frame: Week 0, 5, and 10 ]
    Assessed with MILLIPLEX MAP Human High Sensitivity T Cell Panel - Immunology Multiplex Assay.

  13. Changes in plasma 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels [ Time Frame: Week 0, 5, and 10 ]
    Assessed via LC-MS

  14. Changes in plasma F-2 isoprostane levels [ Time Frame: Week 0, 5, and 10 ]
    Assessed via LC-MS

  15. Changes in plasma progesterone levels [ Time Frame: Week 0, 5, and 10 ]
    Analysis using MILLIPLEX MAP Multi-Species Hormone Magnetic Bead Panel

  16. Changes in plasma estradiol levels [ Time Frame: Week 0, 5, and 10 ]
    Analysis using MILLIPLEX MAP Multi-Species Hormone Magnetic Bead Panel

  17. Changes in plasma testosterone levels [ Time Frame: Week 0, 5, and 10 ]
    Analysis using MILLIPLEX MAP Multi-Species Hormone Magnetic Bead Panel

  18. Changes in plasma cortisol levels [ Time Frame: Week 0, 5, and 10 ]
    Analysis using MILLIPLEX MAP Multi-Species Hormone Magnetic Bead Panel

  19. Changes in plasma cholesterol levels [ Time Frame: Week 0, 5, and 10 ]
    Using a colorimetric assay

  20. Changes in plasma antioxidant capacity [ Time Frame: Week 0, 5, and 10 ]
    Measured using the 2,2'-azino-bis-3-ethylbenzthiazoline-6-sulfonic acid (ABTS) assay

  21. Changes in Vitamin A status [ Time Frame: Week 0, 5, and 10 ]
    Plasma HPLC analysis

  22. Changes in perceived health and attractiveness [ Time Frame: Week 0, 5, and 10 ]
    A perception trial is a validated method used to determine the attractiveness preferences of participants (Lefevre & Perrett, 2015). Images of participants from the intervention trial will be sent to the Department of Psychology at McGill University, where the laboratory coordinator will set up an electronic survey that will display randomized sets of images from the same intervention participant at all timepoints (week 0, 5, and 10) of the intervention, in randomized order of presentation (left and right). A separate group of 60 participants will be recruited to participate in the perception trial and assess the images of the intervention participants. These participants will be trained using a few sample photos and then will be instructed to choose the most attractive and healthy looking face in a forced-choice paradigm for each comparison presented in the electronic survey.

  23. Changes in quality of life assessed by SF-36 questionnaire [ Time Frame: Week 0, 5, and 10 ]
    The short form 36-Item Health Survey 1.0 Questionnaire is a validated questionnaire that will be used to assess QoL as a recent study (Valler-Colomer et al., 2019) demonstrated a consistent association between higher QoL indicators and particular gut microbiota profiles (butyrate-producing Faecalibacterium and Coprococcus bacteria). This survey consists of 36 items that average together to indicate eight scale scores for various health indicators (e.g., emotional well-being, general health, etc.). Scores range from 0-100, with higher scores representing better health. Carotenoid supplementation has also demonstrated improvements in sub-optimal symptoms of physical and emotional health measured via various self-reported questionnaires (Stringham et al., 2018).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy non-menopausal or non-perimenopausal women,
  2. 30-50 years of age,
  3. BMI of 18.5 - 29.9 kg/m2,
  4. Access to a smartphone that has a camera and iOS 11.0 or Android 4.2 and up,
  5. Visible fine to moderate wrinkles on the face (e.g. forehead, crow's feet area, etc.),
  6. Skin yellow color saturation b* value below 15.0,
  7. Fitzpatrick scale of types I, II, & III
  8. Urine pregnancy test of negative
  9. Willing to maintain current physical activity and dietary habits
  10. Willing to refrain from taking natural health products containing carotenoids (beta-carotene, lutein, lycopene, etc.)
  11. Willing to discontinue consumption of probiotic supplements and food containing added probiotics (e.g. yogurts with live, active cultures or supplements) or fermented foods (e.g. Kefir, pickles, etc.) upon screening and for the duration of the study,
  12. Willing to apply the moisturizer provided on every day throughout the study upon admission to the study (about -2 weeks),
  13. Willing to refrain from using any cream (including the moisturizer provided) and makeup on the face for study visits and photo capture (face, eyes and lips),
  14. Able to understand and comply with requirements of the study (e.g. complete all clinical visits, questionnaires, records, and diaries),
  15. Able to provide a written informed consent.

Exclusion Criteria:

  1. Known immunodeficiency (immuno-compromised and immuno-suppressed participant; e.g. AIDS, lymphoma, participants undergoing long-term corticosteroid treatment, chemotherapy and allograft participant),
  2. Known chronic or acute illness (e.g. hepatitis, diabetes, high blood pressure, jaundice, etc.), unless under control via medication,
  3. History of illness or use of any type of drug that may interfere with the investigational product or intervention (e.g. antibiotics) within 1 month of screening (may be eligible to participate after a 2-week washout period),
  4. Known chronic or acute skin condition on the face (e.g. eczema, psoriasis, severe acne, rosacea, etc.),
  5. Facial surgery (e.g. lifting, facial rejuvenation) or chemical treatment (e.g. Botox injection) within 5 years before study start,
  6. Frequent tanning salons, use tanning products, or foresee high exposure to the sun during the study,
  7. Tattoos on the face or palms of the hands,
  8. Milk, soy or yeast allergy,
  9. Routine use of dietary supplements that may interfere with outcomes measured (e.g. anti-oxidant, anti-inflammatory, herbal),
  10. Use of probiotic products in the past 2 weeks (may be eligible to participate after a 2-week washout period),
  11. Allergy to any of the ingredients contained in the moisturizer provided,
  12. Use of antiaging creams containing retinol, glycolic acid, Coenzyme Q, etc. (may be eligible to participate after a 2 weeks washout period upon admission to the study),
  13. Current smoker (tobacco or cannabis),
  14. Excessive alcohol consumption (>1 drink/day),
  15. Drug abuse or addiction,
  16. Bleeding/blood disorder
  17. Psychological disorder
  18. Currently enrolled in another trial
  19. Positive pregnancy test in women of child-bearing potential; breast-feeding or planning on becoming pregnant during the course of the study (determined by a pregnancy test performed at the screening visit),
  20. Women of child-bearing potential not using effective contraception which include:

    • Hormonal contraceptives including combined oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormonal implants
    • Intrauterine devices (IUD) or Intrauterine system (IUS)
    • Tubal ligation
    • Vasectomy of partner
    • Barrier method (condom or occlusive cap with spermicide)
    • Abstinence
  21. Participation in a similar study within 3 months of the screening visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04511052


Contacts
Layout table for location contacts
Contact: Stan Kubow, PhD 514-398-7754 stan.kubow@mcgill.ca

Locations
Layout table for location information
Canada, Quebec
Mary Emily Clinical Nutrition Research Unit Recruiting
Sainte-Anne-de-Bellevue, Quebec, Canada, H9X 2E3
Contact: Lucas Roldos, PhD (c)    438-638-8392    Procarstudy.dhn@mcgill.ca   
Sponsors and Collaborators
McGill University
Lallemand Health Solutions
Layout table for additonal information
Responsible Party: McGill University
ClinicalTrials.gov Identifier: NCT04511052    
Other Study ID Numbers: A12-M57-19B
IT15250 ( Other Grant/Funding Number: MITACS Accelerate )
First Posted: August 12, 2020    Key Record Dates
Last Update Posted: September 5, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by McGill University:
Carotenoid
Microbiome
Skin
Color
Plasma
Additional relevant MeSH terms:
Layout table for MeSH terms
Carotenoids
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs